The Tab Study

Study Contact: tab@utah.edu
Call or text: (385) 977-2445

About

NIDA CTN-0152 Evaluation of Tirzepatide As an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (TAB). We are conducting a research study to find out if adding tirzepatide-a medication currently approved for type 2 diabetes (Mounjaro®) and weight management (Zepbound®)-can help people with opioid use disorder (OUD) stay in treatment, reduce cravings and substance use, and improve sleep when used alongside buprenorphine (brand names include Suboxone®, Zubsolv®, Brixadi®, and Sublocade®). Tirzepatide is not currently FDA-approved for treating OUD. Participants will be randomly assigned to tirzepatide or placebo.

ClinicalTrials.org identifier: NCT06651177

Who are we looking for?

We are looking for individuals who:

Are at least 18 years old
Have moderate to severe OUD
Have started buprenorphine treatment for OUD within the past 4 weeks

What’s involved?

Your participation in the study would last about 31 weeks. This would include about 1 week for screening and baseline assessments, 26 weeks of active treatment, and one follow up visit at about study week 30. In all, you will attend about 28 visits. Three of these visits, which will occur at study months 1, 3, and 6, will be longer than the usual weekly visits. Your participation would be entirely voluntary. As part of the study, you will receive a Fitbit™ and a cell phone; if you are randomized, you will be allowed to keep these devices after your study participation concludes. You will be compensated for time & travel.

TAB Site Locations